The biggest question if your holding long regarding osip, imcl, and eyet is how good is the competition and how good do those drugs work when combined with various drugs. That answer will only come by waiting for clinical data. I placed my money on erbitux but I would have to say at this point I think the egf'r market is a toss up.
As far as genr is concerned, if they continue show good efficacy I think EYET's stock price is a good way to measure the possibilities.
Market Data 
Markets 
AI
